SummaryBackground: Malignant ascites is a frequent complication in gastrointestinal malignancy and is unresponsive to systemic therapies. Therapeutic options are limited, and repeated paracentesis is associated with increased loss of fluids and proteins, and impaired quality of life. The bi-specific trifunctional antibody catumaxomab has been approved for the treatment of refractory ascites. It has been proposed that repeated application leads to formation of human anti-mouse antibodies with a decrease in effectiveness and potentially hypersensitivity reactions. Case Report: Here we report on the repeated application of catumaxomab in 2 patients with advanced signet cell gastric cancer. Repeated application was safe and effective in decreasing the frequency of paracentesis in 1 patient. No hypersensitivity reactions beyond the immune-mediated side effects were observed with the application of catumaxomab. 1 patient experienced an inflammatory response with acute deterioration of kidney function during the first cycle but recovered quickly. Re-challenge with catumaxomab did not produce an inflammatory reaction in the 2 cases. Conclusion: Overall, the repeated treatment was associated with a beneficial effect on puncture-free survival in 1 patient, and appears to be a treatment option in selected patients with gastrointestinal malignancy.

1.
Runyon BA: Care of patients with ascites. N Engl J Med 1994;330:337-342.
[PubMed]
2.
Ayantunde AA, Parsons SL: Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007;18:945-949.
[PubMed]
3.
Sugarbaker PH, Yu W, Yonemura Y: Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol 2003;21:233-248.
[PubMed]
4.
Wimberger P, Gilet H, Gonschior AK, Heiss MM, Moehler M, Oskay-Oezcelik G, Al-Batran SE, Schmalfeldt B, Schmittel A, Schulze E, Parsons SL: Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol 2012;23:1979-1985.
[PubMed]
5.
Roviello F, Marrelli D, Neri A, Cerretani D, de Manzoni G, Pedrazzani C, Cioppa T, Nastri G, Giorgi G, Pinto E: Treatment of peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion (IHCP): postoperative outcome and risk factors for morbidity. World J Surg 2006;30:2033-2040; discussion 2041-2032.
[PubMed]
6.
Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL: The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010;127:2209-2221.
[PubMed]
7.
Sehouli J, Wimberger P, Vergote IB, Rosenberg P, Schneeweiss A, Bokemeyer C, Salat C, Scambia G, Berton-Rigaud D, Siena S, Santoro A, Cervantes-Ruiperez A, Guastalla J, Tournigand C, Colombo N, Dudnitchenko A, Bondar V, Westermann AM, Lordick F: Catumaxomab with and without prednisolone in patients with malignant ascites due to epithelial cancer: results from the phase IIIb CASIMAS study. J Clin Oncol 2012;30:e13097.
[PubMed]
8.
Pietzner K, Vergote I, Santoro A, Marme F, Rosenberg P, Friccius-Quecke H, Sehouli J: Results of a phase II clinical trial to evaluate a re-challenge of intraperitoneal catumaxomab for treatment of malignant ascites (MA) due to epithelial cancer (SECIMAS). J Clin Oncol 2013;31(suppl):abstr 5582.
9.
Ott MG, Marme F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, Essing MM, Linke R, Seimetz D: Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer 2012;130:2195-2203.
[PubMed]
10.
Pietzner K, Jager M, Schoberth A, Oskay-Ozcelik G, Kuhberg M, Lindhofer H, Sehouli J: First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report. Med Oncol 2012;29:1391-1396.
[PubMed]
11.
Petrelli F, Borgonovo K, Lonati V, Elia S, Barni S: Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer. Target Oncol 2013;8:291-294.
[PubMed]
12.
Woopen H, Pietzner K, Darb-Esfahani S, Oskay-Oezcelik G, Sehouli J: Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature. Med Oncol 2012;29:3416-3420.
[PubMed]
13.
Moehler M, Sieben M, Roth S, Springsguth F, Leuchs B, Zeidler M, Dinsart C, Rommelaere J, Galle PR: Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus h-1. BMC Cancer 2011;11:464.
[PubMed]
You do not currently have access to this content.